Navigation Links
Nucleoside in Medical News

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients

... more potent than Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies ... toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in ... three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated ...

HIV Drugs Linked to Increased Risk of Heart Attack

... drugs, which include a protease inhibitor and a nucleoside reverse transcriptase inhibitor such as abacavir ... heart attack. For commonly used drugs called nucleoside reverse transcriptase inhibitors such as ... increased risk for heart attack. However, the nucleoside reverse transcriptase inhibitors abacavir and ...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

... oncology products, 4-thio Ara-C (Thiarabine), which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium ... About Thiarabine : Thiarabine, or 4-thio Ara-C, is a next generation nucleoside analogue licensed from Southern Research Institute. The compound has been ...

Pharmasset to Webcast an Investor Event from the AASLD Meeting

... on the AASLD website (AASLD.org). R7128 "Antiviral Activity Of The HCV nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 And 3 Prior Non-Responders: ... M. M. Berrey. Abstract: LB10 "Potent Antiviral Response To The HCV nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-Ifn And Ribavirin: ...

Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels

... for the Study of Liver Diseases (AASLD). Patients in this cohort were nucleoside naive e-antigen (HBeAg)-positive patients with chronic hepatitis B ... (entecavir) Discovered at Bristol-Myers Squibb, BARACLUDE is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus ...

Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C

... R7128 is an orally administered prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of hepatitis C virus (HCV) that is being ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

... autoimmune diseases. BioCryst has two product candidates in pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues ...

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development

... of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates. R7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the ...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

TriLink BioTechnologies, Inc. Announces Sales and License Agreement With Glen Research Corporation for CleanAmp(TM) Amidites

... said TriLink CEO, Dr. Richard Hogrefe. About TriLink TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR ...

Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

NEJM study points to new era in hepatitis C treatment

... is an antiviral drug given by injection that is also used to treat HIV and hepatitis B; it works in conjunction with a drug called ribavirin, a nucleoside analogue, to suppress the viral activity of hepatitis C. Side effects can include severe flu-like symptoms, depression, fatigue, insomnia and anemia. ...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

... Access recently announced completed the acquisition of MacroChem Corporation. This acquisition provides Access with Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology

... Society of Clinical Oncology (ASCO) being held in Orlando, Florida from May 29-June 2. Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase (PNP), a purine salvage pathway enzyme that is essential for the proliferation of T-cells and B-cells. The poster entitled ...

Pharmasset to Present at Deutsche Bank Healthcare Conference

... of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration ...

Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities

... of Scientific and Technical Research (COST) organization. Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature ...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

... clinical exploration of ANA598 in combination with interferon-alpha and with direct antivirals now in development, including protease inhibitors and nucleoside polymerase inhibitors. Long-Term Chronic Toxicology Studies of ANA598. In September 2008, Anadys initiated long-term, chronic toxicology ...

Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID

... applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. SR9025 is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For more information about MacroChem, call David P. Luci, ...

New therapy prevents dangerous side effect for lymphoma patients

... around 10 percent. The key ingredient in pushing the MDS rate to zero, Samaniego says, was substitution of fludarabine with pentostatin. Both are nucleoside analogs, which interfere with DNA reproduction, and target lymphoid cells, making them attractive drugs for lymphomas. Earlier research indicated ...

How to select anti-hepatitis B virus agents for drug-resistance patients?

... cirrhosis, or hepatocellular carcinoma. The principal treatment for chronic hepatitis B (CHB) involves the use of interferon alpha (IFN-a) or nucleoside analogs. In vitro analysis of clinical HBV isolates is currently difficult for lacking of HBV cellular culture model A research article to be ...

A potential approach to treatment of hepatitis B virus infection

... is effective in only approximately one-third of the patients and produces considerable side effects. Long-term treatment with the second-generation nucleoside analogue lamivudine (lam) efficiently inhibits HBV replication with frequent viral polymerase mutations. We found that HBV infection triggered an ...

New treatment therapy helps inhibit hepatitis C

... Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology , a journal published by ...

Pharmasset Reports Financial Results for Quarter Ended March 31, 2008

... J. Conrad as a member of our Board of Directors and the Nominating and Corporate Governance Committee. -- Advanced a new series of proprietary nucleoside analogs that have demonstrated potent anti-HCV activity. Anticipated Highlights -- Initiating dosing and announcing preliminary results of ...

Study Supports Popular HIV Drug Regimen

... records of 753 HIV-positive patients at 55 treatment centers. The patients took one of three regimens, two of which included older drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Doctors consider them to be effective, but they can cause a variety of side effects. The researchers ...

HIV drugs, Abacavir and Didanosine increase the risk of heart attack

... including a possible increase in the risk of heart attack. Recent analysis has focused on a class of drugs, not previously examined, known as the nucleoside analogues, which inhibit the HIV virus by preventing it from multiplying. This class of drugs includes Stavudine, Zidovudine, Lamivudine, Abacavir ...

Test Detects Sensitivity to HIV Drug

... the AIDS drug abacavir, also known by the brand name Ziagen, which is found in compound drugs known as Trizivir and Epzicom. The drug is known as a nucleoside reverse transcriptase inhibitor and works by preventing the AIDS virus from going through the motions of multiplying. About 8 percent of patients ...

IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide

... and entry inhibitor compounds early in development, and in December 2006 IPM reached an agreement with Gilead Sciences to develop tenofovir (PMPA), a nucleoside reverse transcriptase inhibitor. HIV/AIDS ranks among the world's most devastating diseases because it has spread rapidly and mainly afflicts ...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... of 2% compared to the same period in 2006 (2006: $275 million), but a decrease of approximately 3% on a constant exchange rate basis. While the nucleoside analogue market for HIV has continued to grow, competitive pressures within the market have increased leading to a decline in 3TC sales. ZEFFIX - ...

VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting

... excitement related to our development programs." About VQD-002 VQD-002 Triciribine phosphate (TCN-PM) is a novel, first in class tricyclic nucleoside that inhibits phosphorylated Akt (protein kinase B). Akt is a serine/threonine protein kinase, which is not normally active in human cells, but is ...

Is There Any Clinical Benefit to Staying on a Failing Regimen?

... ritonavir-boosted protease inhibitors. 43% of patients were receiving two nucleoside analogues and a single protease inhibitor, while 39% were receiving a ... Additionally, patients on 3TC (lamivudine) showed a slower accumulation of nucleoside mutations and thymidine analogue mutations (TAMs). According to the ...

Reducing the Risk of Protease Inhibitor-Related Atherosclerosis

... from the University of Kentucky found that when mice were given a nucleoside reverse transcriptase inhibitor (NRTI) and a protease inhibitor in ... J. Smart. “To our knowledge, these are the first data that indicate that nucleoside reverse transcriptase inhibitors can limit the atherogenic (tendency to ...

Study Compares First-Line Drug Therapies For Treating HIV

... evaluated in the randomized trial, the therapy consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) with efavirenz, a non-nucleoside ... drugs used in the clinical trial are approved for the treatment of HIV. nucleoside reverse transcriptase inhibitors, or NRTIs, prevent healthy T cells from ...

Resistance Already Emerging in First Months of Treatment Despite Viral Load Decline

... compared to a normal resistance assay threshold of around 10-15%. The drug regimens varied, but all contained 3TC combined with another nucleoside reverse transcriptase inhibitor (NRTI) plus either a protease inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI). ...
Other Contents
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... The North American perimeter security market is ... to 2019. Although the U.S. market holds a larger share ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
Other TagsOther Tags